TABLE 1.
Percentage Achieving Durable Viral Suppression by Demographic Characteristics Across all Sites and Within Each Site’s Study Arms
| Characteristics | Intervention N (%) | Standard of Care N (%) | P |
|---|---|---|---|
| Total | |||
| All sites | 415/958 (43.3) | 396/935 (42.4) | 0.67 |
| Connecticut (CT) | 155/332 (46.7) | 145/322 (45.0) | 0.67 |
| Massachusetts (MA) | 129/317 (40.7) | 139/313 (44.4) | 0.35 |
| Philadelphia (PHL) | 131/309 (42.4) | 112/300 (37.3) | 0.20 |
| Male (birth sex) | |||
| All sites | 305/672 (45.4) | 267/644 (41.5) | 0.15 |
| CT | 110/211 (52.1) | 83/197 (42.1) | 0.04 |
| MA | 95/226 (42.0) | 107/232 (46.1) | 0.38 |
| PHL | 100/235 (42.6) | 77/215 (35.8) | 0.14 |
| Race/Ethnicity | |||
| All sites | |||
| Non-Hispanic Black | 182/460 (39.6) | 184/455 (40.4) | 0.79 |
| Non-Hispanic White | 109/237 (46.0) | 117/245 (47.8) | 0.57 |
| Hispanic/Latino | 117/239 (49.0) | 81/213 (38.0) | 0.12 |
| Other | 7/22 (31.8) | 12/22 (54.5) | 0.13 |
| CT | |||
| Non-Hispanic Black | 49/123 (39.4) | 54/141 (38.3) | 0.80 |
| Non-Hispanic White | 30/63 (47.6) | 38/72 (52.8) | 0.55 |
| Hispanic/Latino | 75/138 (54.4) | 52/104 (50.0) | 0.50 |
| Other | 1/8 (12.5) | 1/5 (20.0) | 1.00 |
| MA | |||
| Non-Hispanic Black | 47/134 (35.1) | 61/119 (51.3) | 0.01 |
| Non-Hispanic White | 54/113 (47.8) | 55/118 (46.6) | 0.86 |
| Hispanic/Latino | 25/65 (38.5) | 18/69 (26.1) | 0.13 |
| Other | 3/5 (60.0) | 5/7 (71.4) | 1.00 |
| PHL | |||
| Non-Hispanic Black | 86/203 (42.4) | 69/195 (35.4) | 0.15 |
| Non-Hispanic White | 25/61 (41.0) | 26/55 (47.3) | 0.50 |
| Hispanic/Latino | 17/36 (47.2) | 11/40 (27.5) | 0.08 |
| Other | 3/9 (33.3) | 6/10 (60.0) | 0.37 |
| Age, years | |||
| All sites | |||
| 18–29 | 42/133 (31.6) | 38/126 (30.2) | 0.80 |
| 30–39 | 77/213 (36.2) | 83/221 (37.6) | 0.76 |
| 40–49 | 107/243 (44.0) | 99/234 (42.3) | 0.70 |
| 50–59 | 127/251 (50.6) | 121/258 (46.9) | 0.40 |
| 60 years or older | 62/118 (52.5) | 54/94 (57.5) | 0.48 |
| CT | |||
| 18–29 | 12/40 (30.0) | 14/51(27.5) | 0.79 |
| 30–39 | 23/59 (39.0) | 24/59 (40.7) | 0.85 |
| 40–49 | 35/90 (39.0) | 36/82 (43.9) | 0.50 |
| 50–59 | 55/94 (58.5) | 42/85 (49.4) | 0.22 |
| 60 years or older | 30/49 (61.2) | 29/45 (64.4) | 0.75 |
| MA | |||
| 18–29 | 10/32 (31.3) | 11/29 (37.9) | 0.58 |
| 30–39 | 28/77 (36.4) | 33/74 (44.6) | 0.30 |
| 40–49 | 34/77 (44.2) | 31/78 (39.7) | 0.58 |
| 50–59 | 39/89 (43.8) | 47/99 (47.5) | 0.62 |
| 60 years or older | 18/42 (42.9) | 16/31 (51.6) | 0.46 |
| PHL | |||
| 18–29 | 20/61 (32.8) | 13/46 (28.3) | 0.62 |
| 30–39 | 26/77 (33.8) | 26/88 (29.6) | 0.56 |
| 40–49 | 38/76 (50.0) | 32/74 (43.2) | 0.41 |
| 50–59 | 33/68 (48.5) | 32/74 (43.2) | 0.53 |
| 60 years or older | 14/27 (51.9) | 9/18 (50.0) | 0.90 |
| Transmission category * | |||
| All sites | |||
| MSM | 167/376 (44.4) | 209/359 (58.2) | 0.18 |
| IDU | 95/198 (49.0) | 79/174 (45.4) | 0.62 |
| HET | 92/213 (43.2) | 95/223 (42.6) | 0.90 |
| Other | 61/171 (35.7) | 80/179 (44.7) | 0.09 |
| CT | |||
| MSM | 42/94 (44.7) | 38/100 (38.0) | 0.34 |
| IDU | 55/95 (57.9) | 44/83 (53.0) | 0.51 |
| HET | 37/97 (38.1) | 42/93 (45.2) | 0.33 |
| Other | 21/46 (45.7) | 21/46 (45.7) | 1.00 |
| MA | |||
| MSM | 64/133 (48.1) | 63/129 (48.8) | 0.91 |
| IDU | 9/34 (26.5) | 13/40 (32.5) | 0.57 |
| HET | 24/47 (51.1) | 17/43 (39.5) | 0.27 |
| Other | 32/103 (31.1) | 46/101 (45.5) | 0.03 |
| PHL | |||
| MSM | 61/149 (41) | 41/130 (31.5) | 0.10 |
| IDU | 31/69 (44.9) | 22/51 (43.1) | 0.85 |
| HET | 31/69 (44.9) | 36/87 (41.4) | 0.66 |
| Other | 8/22 (36.4) | 13/32 (40.6) | 0.75 |
| Viral suppression in the year before randomization | |||
| All sites | |||
| No | 33/180 (18.3) | 30/184 (16.3) | 0.61 |
| Yes | 286/538 (53.2) | 287/524 (54.8) | 0.60 |
| CT | |||
| No | 12/57 (21.1) | 11/54 (20.4) | 0.93 |
| Yes | 86/159 (54.1) | 88/163 (54.0) | 0.99 |
| MA | |||
| No | 9/54 (16.7) | 7/52 (13.5) | 0.64 |
| Yes | 100/188 (53.2) | 120/202 (59.4) | 0.22 |
| PHL | |||
| No | 12/69 (17.4) | 12/78 (15.4) | 0.74 |
| Yes | 100/191 (52.4) | 79/159 (49.7) | 0.62 |
| CD4 count in the year before randomization | |||
| All sites | |||
| ≤50 cells/μL | 82/208 (39.4) | 73/205 (35.6) | 0.42 |
| 51–199 cells/μL | 117/275 (42.6) | 125/278 (45.0) | 0.57 |
| 200–350 cells/μL | 97/205 (47.3) | 72/173 (41.6) | 0.27 |
| 351–499 cells/μL | 55/127 (43.3) | 60/140 (42.9) | 0.94 |
| ≥ 500 cells/μL | 64/143 (44.8) | 66/139 (47.5) | 0.65 |
| CT | |||
| ≤50 cells/μL | 33/78 (42.3) | 23/71 (32.4) | 0.21 |
| 51–199 cells/μL | 51/107 (47.7) | 56/106 (52.8) | 0.45 |
| 200–350 cells/μL | 19/45 (42.2) | 28/56 (50.0) | 0.44 |
| 351–499 cells/μL | 23/42 (54.8) | 17/40 (42.5) | 0.27 |
| ≥500 cells/μL | 29/60 (48.3) | 21/49 (42.9) | 0.57 |
| MA | |||
| ≤50 cells/μL | 27/69 (39.1) | 26/58 (44.8) | 0.52 |
| 51–199 cells/μL | 32/82 (39.0) | 32/83 (38.6) | 0.95 |
| 200–350 cells/μL | 36/72 (50.0) | 25/58 (43.1) | 0.43 |
| 351–499 cells/μL | 16/47 (34.0) | 28/60 (46.7) | 0.19 |
| ≥500 cells/μL | 18/47 (38.3) | 28/54 (51.9) | 0.17 |
| PHL | |||
| ≤50 cells/μL | 22/61 (36.1) | 24/76 (31.6) | 0.58 |
| 51–199 cells/μL | 34/86 (39.5) | 37/89 (41.6) | 0.78 |
| 200–350 cells/μL | 42/88 (47.7) | 19/59 (32.2) | 0.06 |
| 351–499 cells/μL | 16/38 (42.1) | 15/40 (37.5) | 0.68 |
| ≥500 cells/μL | 17/36 (47.2) | 17/36 (47.2) | 1.00 |
*
HET = heterosexual; IDU = injection drug use; MSM = men who have sex with men; Other = perinatal, no identified risk, or not in record. Year 2016–2019 (N= 1893).